Cancer News: Leukemia and lymphoma

FDA approves drug for relapsed or refractory peripheral T-cell lymphoma

The US FDA has granted accelerated approval to belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Drug against specific blood cancers approved by the US FDA

The US FDA approved idealisib against relapsed chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma.

Chronic Lymphocytic Leukemia (CLL) drug approved in Europe

EU regulators approved obinutuzumab for chronic lymphocytic leukemia (CLL) patients, a type of cancer that starts from white blood cells in the bone marrow.